Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KAINOS LaboratoriesTSE:4556 39 PS Ratio is 1.78 as of Jul. 17, 2026, which is 93% above its 10-year median of 0.92. GuruFocus rates TSE:4556 with a GF Score™ of 39/100 and a GF Value™ of 円1,282.66 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, KAINOS Laboratories ranks better than 64.84% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, KAINOS Laboratories's share price is 円2268.00.
KAINOS Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,273.56. Hence, KAINOS Laboratories's PS Ratio for today is 1.78.
Warning Sign:
KAINOS Laboratories Inc stock PS Ratio (=1.75) is close to 10-year high of 1.81.
The historical rank and industry rank for KAINOS Laboratories's PS Ratio or its related term are showing as below:
TSE:4556'
s PS Ratio Range Over the Past 10 Years
Min: 0.41 Med: 0.92 Max: 1.81
Current: 1.78
During the past 13 years, KAINOS Laboratories's highest PS Ratio was 1.81. The lowest was 0.41. And the median was 0.92.
TSE:4556's PS Ratio is ranked better than 64.84% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.86
vs TSE:4556: 1.78
During the past 12 months, the average Revenue per Share Growth Rate of KAINOS Laboratories was 3.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 0.90% per year.
During the past 13 years, KAINOS Laboratories's highest 3-Year average Revenue per Share Growth Rate was 10.60% per year. The lowest was -5.20% per year. And the median was 2.45% per year.
Back to Basics: PS Ratio
KAINOS Laboratories (TSE:4556) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
KAINOS Laboratories PS Ratio Related Terms
KAINOS Laboratories PS Ratio Historical Data
* Premium members only.
The historical data trend for KAINOS Laboratories's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KAINOS Laboratories PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's PS Ratio distribution charts can be found below:
* The bar in red indicates where KAINOS Laboratories's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
KAINOS Laboratories's Share Price of today is 円2268.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. KAINOS Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,273.56.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
KAINOS Laboratories (TSE:4556) has a PS Ratio of 1.78 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on KAINOS Laboratories and its competitors. This is 93% above median its historical median of 0.92. Over the past decade, KAINOS Laboratories' PS Ratio has ranged from 0.41 to 1.81. According to the industry distribution chart, KAINOS Laboratories ranks #283 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 35.2%.
Is KAINOS Laboratories' PS Ratio too high?
KAINOS Laboratories' current PS Ratio of 1.78 is 93% above median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 1.81. The Medical Devices & Instruments industry median PS Ratio is 2.86. KAINOS Laboratories' value of 1.78 is 37.8% below this industry median. Based on the distribution chart, KAINOS Laboratories ranks #283 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, KAINOS Laboratories has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, KAINOS Laboratories ranks #283 out of 805 companies for PS Ratio. This puts KAINOS Laboratories in the upper half of its industry. The industry median PS Ratio is 2.86. KAINOS Laboratories' value of 1.78 is 37.8% below this benchmark. Historically, KAINOS Laboratories' own PS Ratio has ranged from 0.41 to 1.81 over the past decade. While the company's 10-year median is 0.92 vs. the industry median of 2.86, KAINOS Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KAINOS Laboratories's current PS Ratio of 1.78 is 37.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on KAINOS Laboratories and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current PS Ratio is 1.78, which is 93% above median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,282.66, compared to a current price of 円2,268.00 — trading 76.8% above its estimated fair value. The current PS Ratio is 1.78, which is 93% above median its 10-year median of 0.92 and 37.8% below the Medical Devices & Instruments industry median of 2.86. KAINOS Laboratories' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current PS Ratio is 1.78 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?
Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued.
The current stock price of 円2,268.00 is trading 76.8% above its estimated GF Value™ of 円1,282.66.
GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.
Key valuation signals for TSE:4556:
PS Ratio: 1.78 (93% above median its 10-year median of 0.92)
GF Value™: 円1,282.66 vs. price of 円2,268.00 (76.8% above fair value)
Industry Position: 37.8% below the Medical Devices & Instruments median (#283 of 805)
No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
39GF Score
Get the complete analysis for TSE:4556
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4556 has been successfully added to your 
